Notogen Inc.

Notogen is a biotechnology company developing a biologic regenerative therapeutic for disc degeneration. Notogen’s lead candidate, NTG-101, is a targeted, non-surgical, non-cellular protein-based biologic for the treatment of disc degeneration disease. Based on more than 20 years of research, this novel therapeutic has the potential to improve the lives of millions of people worldwide who suffer from chronic back and neck pain and dysfunction caused by disc degeneration.

CONTACT: Gary Margolis, CEO
gmargolis@notogen.com